The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience

Table 1

Patients characteristics.

Characteristics	Value
Sex, no (%)
Male	46 (52)
Female	42 (48)
Median age at diagnosis (range)	51 (21–83)
Hasford score at diagnosis, no (%)
Low risk (LR)	57 (65)
Intermediate risk (IR)	31 (35)
Sokal score at diagnosis, no (%)
Low risk	60 (68)
Intermediate risk	20 (23)
High risk	8 ()
EUTOS score at diagnosis, no (%)
Low risk	65 (74)
High risk	23 (26)
Hasford score, median value in LR group [min–max]	555 [0–766]
Hasford score, median value in IR group [min–max]	998 [415–1450]
MMR lost on imatinib (assessed by Hasford score) no (%)
Low risk	20 (35)
Intermediate risk	22 (71)
Median time to MMR loss (range) [months]	47 (12–108)
2G-TKI, no (%)
Dasatinib 100 mg	21 (50)
Nilotinib 800 mg	21 (50)
MMR at 3 months of 2G-TKI, no (%)
Low risk	19/20 (86)
Intermediate risk	9/22 (41)
MMR at 18 months of 2G-TKI, no (%)
Low risk	20/20 (100)
Intermediate risk	16/22 (73)
MR ≥ 4.0 at 3 months of 2G-TKI
Low risk	10/20 (50)
Intermediate risk	4/22 (18)
MR ≥ 4.0 at 18 months of 2G-TKI
Low risk	17/20 (77)
Intermediate risk	8/22 (37)